Lexicon Pharmaceuticals’ Study On Sotagliflozin Published In The Lancet Diabetes & Endocrinology Research Paper

Lexicon Pharmaceuticals announced that The Lancet Diabetes & Endocrinology has published a study on sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, highlighting its ability to lower the risk of major cardiovascular events. The research, based on a secondary analysis of the SCORED trial, found that sotagliflozin significantly reduced heart attacks, strokes, and major adverse cardiovascular events (MACE) in patients with type 2 diabetes (T2D), chronic kidney disease (CKD), and high cardiovascular risk.

Deepak L. Bhatt, MD, MPH, MBA, FACC, FAHA, FESC, MSCAI, Director of the Mount Sinai Fuster Heart Hospital, and the Dr. Valentin Fuster Professor of Cardiovascular Medicine at the Icahn School of Medicine at Mount Sinai, New York, NY. The Icahn School of Medicine receives research funding for Dr Bhatt’s role as the Chair of SCORED, commented, “Our research team found that sotagliflozin is the only SGLT inhibitor to demonstrate significant reduction of both heart attack and stroke.”

The SCORED trial, a double-masked, placebo-controlled study, analysed MACE outcomes, including cardiovascular death, nonfatal heart attacks, and nonfatal strokes. The results showed a lower MACE rate in the sotagliflozin group (4.8 events per 100 person-years) compared to placebo (6.3 events per 100 person-years), with a hazard ratio. The drug also significantly reduced the risk of heart attacks and strokes. These findings suggest that sotagliflozin offers cardiovascular protection beyond other SGLT inhibitors, reinforcing its potential for high-risk patients. 

“When you look at the published and presented findings holistically, you get a clear picture of how and why sotagliflozin stands apart from all other SGLT inhibitors,” mentioned Craig Granowitz, M.D., Ph.D., Lexicon’s senior vice president and chief medical officer.